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Background. As yet, no population-based prospective studies have been conducted to investigate the incidence and clinical outcome
of glioblastoma (GBM) or the diffusion and impact of the current standard therapeutic approach in newly diagnosed patients younger
than aged 70 years.
Methods. Data on all new cases of primary brain tumors observed from January 1, 2009, to December 31, 2010, in adults residing
within the Emilia-Romagna region were recorded in a prospective registry in the Project of Emilia Romagna on Neuro-Oncology
(PERNO). Based on the data from this registry, a prospective evaluation was made of the treatment efficacy and outcome in GBM
patients.
Results. Two hundred sixty-seven GBM patients (median age, 64 y; range, 29–84 y) were enrolled. The median overall survival (OS) was
10.7 months (95% CI, 9.2–12.4). The 139 patients ≤aged 70 years who were given standard temozolomide treatment concomitant
with and adjuvant to radiotherapy had a median OS of 16.4 months (95% CI, 14.0–18.5). With multivariate analysis, OS correlated
significantly with KPS (HR¼ 0.458; 95% CI, 0.248–0.847; P¼ .0127), MGMT methylation status (HR¼ 0.612; 95% CI, 0.388–0.966; P¼
.0350), and treatment received in a high versus low-volume center (HR¼ 0.56; 95% CI, 0.328–0.986; P¼ .0446).
Conclusions. The median OS following standard temozolomide treatment concurrent with and adjuvant to radiotherapy given to
(72.8% of) patients aged ≤70 years is consistent with findings reported from randomized phase III trials. The volume and expertise
of the treatment center should be further investigated as a prognostic factor.
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Glioblastoma multiforme (GBM) is the most common and aggres-
sive glioma in adults, with an incidence of 3 to 4 new cases per
100 000 inhabitants per year.1 Despite advances in treatment
modalities, the prognosis for GBM remains poor, with a 10% prob-
ability of survival at 5 years.2
The standard-of-care treatment for newly diagnosed GBM was
established in 2005, when findings made in a randomized phase
III trial (EORTC 26981–22981 /NCIC CE3 [EORTC/NCIC]) demon-
strated that temozolomide concurrent with and adjuvant to
radiotherapy was more effective than radiotherapy alone.3
Results obtained from one phase III clinical trial neither warrant
transferability to clinical practice nor reliably demonstrate a sur-
vival benefit for the entire GBM population. The impact of this
combined approach has been evaluated in many retrospective
population studies,4 – 6 but no findings from a prospective study
have been reported in the literature so far.
Methods
A primary brain tumor (PBT) registry, formerly known as the Pro-
ject of Emilia-Romagna Region on Neuro-Oncology (PERNO),
funded by the Italian Ministry of Health, was created in the
Emilia-Romagna region in 2008. The region had 4 223 591 inhab-
itants and a homogeneous distribution of specialized tertiary can-
cer care hospitals in 2008, with well-distributed neurosurgery,
oncology, and radiotherapy departments and no socioeconomic
or geographic variations in access to health care.
The cases were recorded on the basis of clinical findings and
neuroimaging results leading to a suspicion of PBT. The following
data were sent to the centralized registry database on an elec-
tronic clinical record form: diagnosis code by observing center,
name of recording physician, date of first observation, initials of
patient, date of birth, and sex. Capture-recapture analysis7 was
performed using independent information sources to assess the
completeness of each case record. In this multiple-record system,
all individual specialists from the centers (n¼ 7) participating in
the PERNO project communicated the contact details of their
new patients to the registry staff to be incorporated into a single,
comprehensive record for each case with input from multiple
sources (neuroradiologist, neurosurgeon, neuropathologist, neu-
rologist, radiotherapist, and oncologist) during the entire period
of diagnosis and treatment. Virtually all PBT patients within the
Emilia-Romagna region were thus registered in the above time
interval.
The registry staff assigned each case an identification code and
maintained communication with other research units to assure
that all patients were included in the 5 parallel subprojects
(ie, GBM clinical pathways, epilepsy outcome, translational re-
search, neuroradiological CT perfusion). The completeness of
case records in the registry was verified by checking International
Classification of Disease discharge codes for PBTs from neurosurgi-
cal, neurological, radiotherapy, and oncological services. Further-
more, in order to check recruitment accuracy, information was
exchanged with other tumor registries in the regional provinces.
As a PERNO subproject, a prospective study on the clinical
pathways of patients with GBM (treatment evaluation and out-
comes analysis included) was conducted between January
2009 and December 2010. For this prospective study, the main
inclusion criteria were histologically proven GBM (according
to the WHO classification), aged ≥18 years, KPS 30%–100%, no
prior surgery for primary brain tumor, and residence within the
Emilia-Romagna region.
When GBM patients entered the study, the following data were
recorded: details on surgery, performance status, data and mo-
dalities of radiotherapy, and chemotherapy treatments. Complet-
ed data forms were sent to the central database. Electronic audit
was used to detect outlier values, inconsistencies and omissions,
and any queries were faxed to the study coordinators for
resolution.
MGMT methylation status was assessed using methylation-
specific PCR as described elsewhere.8 Approval for the project pro-
tocol was obtained from the ethical committee of each respective
participating center. Before patient registration, fully informed
consent in writing was obtained according to International Con-
ference on Harmonisation/Good Clinical Practice, and national
regulations.
Statistical Analysis
Survival data, processed using Kaplan-Meier methods to estimate
survival functions, were analyzed by means of Cox models to
assess the relevance of potential prognostic factors. Due to differ-
ences in the expected prognosis and treatments recommenda-
tions, a separate evaluation was made of patients aged ≤70
years who were treated with temozolomide concurrent with
and adjuvant to radiotherapy. A comparison was made between
the referring center and the other centers in terms of age (not di-
chotomized), KPS, and extent of surgery using Student t test for
the first 2 variables and the chi-square test for the latter variables.
The cutoff for significance level was P, .05. All analyses were
made using SAS System software (version 9.2). At the time of
analysis, 221 patients (82.8%) had died.
Results
From January 1, 2009, to December 31, 2010, 398 PBT cases were
included in the register, and 267 cases with histologically proven
GBM were enrolled into the prospective subproject (Fig. 1)
(Table 1). Median accrual by center was 28 (range, 6–63) cases.
Ten patients migrated outside the Emilia-Romagna region for
neurosurgery (3.7%), but all returned to the Emilia-Romagna re-
gion for postsurgical treatment.
Of the 257 (96.3%) patients who underwent resection within
the Emilia-Romagna region, 241 (93.8%) had postsurgical scans
with CT/MRI and 162 (67.2%) with contrast enhancement. The
median time interval between surgery and histological diagnosis
was 8 (range, 2–30) days.
Median OS in the entire population (n¼ 267) was 10.7 months
(95% CI, 9.2–12.4; range, 0.1–40.6 mo).
Fifty-six of the 267 GBM patients (21.0%) did not receive post-
surgical radiotherapy due to rapid clinical deterioration (n¼ 41;
15.4%), patient refusal (n¼ 8; 3.0%), postsurgical complications
(n¼ 6; 2.2%), or tumor size (n¼ 1; 0.4%). The median OS in pa-
tients not receiving any postsurgical treatment was 3.0 months
(95% CI, 2.3–4.5).
Two patients migrated to other Italian regions after surgery,
and 209 patients (78.3%) received postsurgical treatment within
the Emilia-Romagna region, with a median time interval between
surgery and start of radiotherapy of 39 (range, 12.0–76.0) days
and a median OS of 13.3 (95% CI, 11.9–15.6) months.
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Forty-three of the 267 patients (20.6%, range per center,
0%–42.9%) were enrolled in clinical trials (31 patients [11.6%]
were aged ≤70 years, and 12, [4.5%] were aged .70 years).
Assessment of MGMT status, undertaken in 181 of 209 (86.6%)
patients, was achieved in 173 (82.8%) cases; 75 of 173 (43.3%)
were methylated, and 98 of 173 (56.7%) were unmethylated.
Findings for univariate and multivariate analysis on the entire
population are reported in Table 2.
Clinical Outcomes in Patients Aged ≤70 Years
One hundred eighty-nine patients were aged ≤70 years (Fig. 1)
(Table 1). One hundred thirty-nine (Table 3) of 189 patients
(72.8%) were treated according to the EORTC/NCIC study.8 Their
median OS was 16.4 months (95% CI, 14.0– 18.5), being 20
months (95% CI, 15.2–27.0) in patients (n¼ 56) with methylated
MGMTand 15.4 months (95% CI, 11.9–17.6) in those with unme-
thylated MGMT status (n¼ 60); this difference in OS was statisti-
cally significant (P¼ .0052 and P¼ .0350 for univariate and
multivariate analysis, respectively).
Survival rates at 1, 2, and 3 years were 66.2% (95% CI, 58.3%–
74.0%), 32.5% (95% CI, 24.5%–40.5%), and 21.3% (95% CI, 12.8–
29.8%), respectively. Survival rates at 1, 2, and 3 years in MGMT
methylated patients were 71.4% (95% CI, 59.6%–83.3%), 45.8%
(95% CI, 32.6%–59.0%), and 34.0% (95% CI, 19.8%–48.1%), re-
spectively, while survival rates at 1, 2, and 3 years for MGMTunme-
thylated patients were 63.3% (95% CI, 51.1%–75.5%), 19.8%
(95% CI, 8.8%–30.8%), and zero, respectively.
Findings for univariate and multivariate analysis are reported
in Table 4.
In the group of patients aged≤70 years and treated accord-
ing to the EORTC/NCIC study, survival rates were higher in the
center that reported a higher number of patients with postsurgi-
cal treatment. With univariate analysis, it was found that having
been treated in the high-volume referral center correlated with a
median survival that was significantly longer than survivals ob-
tained in other centers (24.1 months vs 15.9 months; HR,
0.533; 95% CI, 0.328–0.866; P¼ .0110). An exploratory analysis
was therefore made to evaluate the accrual rate as a continuous
variable; it was found to have no significant impact by univariate
analysis on OS (P¼ .0673). Multivariate analysis was therefore
performed to evaluate the accrual rate as a dichotomous
variable (referral to high-volume center vs other centers): post-
surgical treatment was correlated significantly with OS in
the high-volume center (HR¼ 0.569; 95% CI, 0.328 – 0.986;
P¼ .0446; see Table 4).
No significant differences were found between the referring
center and other centers for relevant clinical factors such as
age (P¼ .0681) and KPS (P¼ .8899), whereas differences were
found between the centers for extent of surgery (P¼ .0164).
Complete resections were performed in 37.8% of cases in the re-
ferral center and 52.9% of cases in other centers (P¼ .3462), par-
tial resections were performed in 54.1% of cases in the referral
center and 28.4% in other centers (P¼ .0156), and biopsies
were performed in 8.1% of cases in the referral center and
18.6% of cases in other centers (P¼ .3996).
Discussion
The PERNO registry, the first in Italy to prospectively record the
incidence of PBTs, was created in order to include all PBT cases
within the Emilia-Romagna region. The present paper reports
the results of a prospective subproject analyzing the newly diag-
nosed GBM population included in this registry and their clinical
outcome.
In the Emilia-Romagna region, radiotherapy alone or com-
bined with chemotherapy was given to 78.3% of the registered
participants, the rate being 82.7% in patients aged≤70 years
and 67.1% in those .aged 70 years. The standard of care for
newly diagnosed GBM patients aged ≤70 years has been estab-
lished by the EORTC/NCIC3 trial, and 72.8% of cases considered in
the present study underwent this treatment protocol (Table 1).
Table 1. Characteristics of patients in the entire glioblastoma population
n¼ 267
Age, y Median age (range) 64 (29–84)
Performance status Median 80%
Range 30%–100%
Extent of surgery,
n (%)
Biopsy 47 (17.6%)
Partial resection 121 (45.3%)
Complete resection 98 (36.7%)
Postsurgical
treatment,
n (%)
≤70 years (n5 189)
No postsurgical treatment 33 (17.3%)
Radiotherapy alone 17 (8.9%)
Temozolomide concomitant with
and adjuvant to radiotherapy
139 (72.8%)
>70 years (n5 78)
No postsurgical treatment 25 (32.9%)
Radiotherapy alone 25 (32.9%)
Temozolomide concomitant with
and adjuvant to radiotherapy
28 (36.8%)
Fig. 1. Patient selection to achieve patients with glioblastoma aged ≤70
years and treated with radiotherapy/temozolomide.
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Our survival data are comparable with those obtained in the
EORTC/NCIC trial and the more recent RTOG 0525 trial,9 as well
data obtained in retrospective registries in North America (United
States and Canada)10,11 and South America (Columbia),12 and
seem better than data from Austria13 and Switzerland.14
In particular, these results are comparable with those reported
in the retrospective Surveillance, Epidemiology and End Results
(SEER) program,6 in which 65% of patients received the combined
treatment according to EORTC/NCIC, followed by an OS of 15
months; 23% of patients who received no postsurgical treatment
had an OS of 2 months.
Population-based data from Switzerland (Canton of Zurich)14
and the Austrian Brain Tumor Registry13 showed a dismal progno-
sis in the entire populations of GBM cases, with an OS in the
general populations of 5–6 months The Swiss registry was com-
piled between 1980 and 1994, before the EORTC/NCIC trial results
were published (2005), and the Austrian data cover the years
2005 to 2006. In the latter preliminary spatial epidemiological
analysis, the authors suggested that potential regional disparities
across the Austrian health care regions may have affected differ-
ences in survival outcomes.13
A low socioeconomic status and its impact on patient care was
also be cited as a cause of worse outcome in United States vet-
eran cases in the national SEER cohort in which the OS for the
GBM veteran patients was 6.5 months compared with 9.0 months
in the SEER cohort.15
All of the above registries, despite their larger sample sizes,
may be biased due to their retrospective nature: data on survival
and treatment were frequently collected in a post-hoc manner.
A major advantage of this prospective population study
was the solid epidemiological method (capture-recapture meth-
od) that allowed inclusion of virtually all GBM cases diagnosed
within the Emilia-Romagna region. Moreover, the prospective
record of patients and their treatment data allowed more com-
prehensive collection of demographic, treatment, and follow-up
information.
The findings reported in the present study also confirm the
prognostic role of MGMT methylation status. Moreover, the
2-year survival rates obtained are comparable with those report-
ed in the EORTC/NCIC and RTOG 0525 studies, both for patients
with MGMT methylated (46% in the PERNO, 49% in the EORTC/
NCIC,2,3 and 47% in the RTOG 0525 trials) and for those with
MGMT unmethylated (20% in the PERNO and 15% in EORTC/
NCIC trials and 20% in the RTOG 0525 trial) status. Although com-
parisons between clinical trials and population studies are always
challenging, the similarities suggest that the results obtained in
the EORTC/NCIC phase III trial are transferable to the general
population of GBM patients aged≤70 years.
Our data confirms the role of known prognostic factors (per-
formance status and MGMT status), while the extent of surgery
appears to have a borderline effect (by multivariate analysis;
P¼ .698) in patients aged≤70 years treated according to the
EORTC/NCIC trial protocol. However, the extent of surgery was
evaluated by taking into account postsurgical CT/MRI with or
without contrast enhancement performed within 48 hours after
surgery in 60% of patients and on the basis of the neurosurgical
report in about 40% of patients.
For the first time in the field of neuro-oncology, we have inves-
tigated the impact of center volume and expertise in postsurgical
treatment as a variable that may influence the outcome of GBM
Table 2. Univariate and multivariate analyses of the entire GBM population
Variable Factor n Univariate Analysis Multivariate Analysis
Hazard Ratio P Value Hazard Ratio P Value
Estimate 95% CI Estimate 95% CI
Age, y 29.4–83.9 267 1.040 1.025–1.056 ,.0001 1.024 1.009–1.040 .0017
KPS, % 100 38 0.319 0.201–0.505 ,.0001 0.473 0.294–0.760 .0020
≤90 229
Extent of surgery Complete 98 0.300a 0.205–0.439 ,.0001 0.383a 0.259–0.566 ,.0001
Partial 121 0.565a 0.397–0.804 0.604a 0.424–0.860
Biopsy 47
Postsurgical radiotherapy Yes 211 0.112 0.078–0.160 ,.0001 0.166 0.114–0.242 ,.0001
No 56
a“biopsy” is the reference class for the Hazard Ratio.
Abbreviation: CI, confidence interval.
Table 3. Characteristics of patients ≤70 years treated according to EORTC
26981-22981 /NCIC CE.3 trial
n¼ 139
Age Median age 59 years
Range 29–70 years
Gender Male 86 (61.9%)
Female 53 (38.1%)
Performance status, n (%) Median (range) 90 (50–100)
90–100 78 (56.1%)
70–80 52 (37.4%)
50–60 9 (6.5%)
Extent of surgery, n (%) Biopsy 22 (15.8%)
Partial resection 49 (35.3%)
Complete resection 68 (48.9%)
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patients, as it does in other cancer types (eg, lung,16 rectal,17 and
ovarian cancer18), and we found that center expertise has an im-
pact (P¼ .0446) on the survival of patients.
The HR of 0.569, found by multivariate analysis, suggests a po-
tential reduction of mortality in the range of 40%. From a clinical
viewpoint, the median OS for cases treated in a center with high
volume and expertise in postsurgical treatment showed a diffe-
rence ( 8 months); this should be confirmed in a larger prospec-
tive study. However, the OS of 16 months found in cases
treated in lower volume centers is in line with data reported in
the EORTC/NCIC trial.2,3
Unlike settings for other cancer types, such as lung carcinoma,
where hospitals with a high volume of surgical resections are fol-
lowed by increased survival16 or, in the rectal and esophageal
cancer setting where surgeon volume17,19 plays a significant
role in prolonging survival, the results in our setting were not
clearly attributable to the surgeon. By multivariate analysis, the
extent of surgical resection had only a borderline effect on OS.
In cases with ovarian carcinoma, findings at multivariate analysis
demonstrated that OS correlated with adherence to NCCN guide-
lines, even if adherence was greater in high-volume rather than
low-volume hospitals and in physicians who treated more pa-
tients. The same claim cannot be made for our GBM population,
which was homogeneous (aged≤70 years) and had standardized
treatment with temozolomide concomitant and adjuvant to ra-
diotherapy. Our findings may have depended on several factors
such as expertise in neuroradiological interpretation, manage-
ment of adverse events, and use of third-line treatments as
well as improvements in administering the best supportive care.
Moreover, the volume analysis was made following protocol, case
accrual being achieved within the Emilia Romagna region, which
is only partially representative of the size of the practice in the
high-volume center.
Given the number of variables tested, there is concern regard-
ing some potential prognostic associations that would be difficult
to estimate within a relatively small patient population, and im-
provements in immediate postsurgical disease assessment are
needed. Therefore, the exploratory data reported in the present
prospective population-based registry study should be confirmed
by a larger prospective study.
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